Nausea: When to See a Doctor and When to Worry

Why Am I Nauseous? Common and Overlooked Causes

Nausea is a protective reflex, not a disease. It originates from coordinated signaling between the gastrointestinal tract, the vestibular system, the chemoreceptor trigger zone (CTZ) in the area postrema, and the vomiting center in the medulla oblongata [1]. Understanding the source narrows the differential and determines urgency.

The most frequent causes in outpatient settings fall into a handful of categories. Viral gastroenteritis (norovirus and rotavirus) accounts for a large share, with the CDC estimating 19 to 21 million cases of norovirus illness per year in the United States alone [2]. Medication-induced nausea ranks second, with NSAIDs, opioids, antibiotics (particularly erythromycin and metronidazole), and SSRIs among the most common culprits. Gastroesophageal reflux disease (GERD) causes nausea in approximately 40% of patients who do not present with classic heartburn, a pattern called "silent reflux" or atypical GERD [3].

Pregnancy-related nausea affects 70 to 80% of pregnant individuals, according to the American College of Obstetricians and Gynecologists, and typically peaks between weeks 6 and 9 of gestation [4]. Hyperemesis gravidarum, the severe form, occurs in roughly 0.3 to 3% of pregnancies and requires medical treatment.

Overlooked triggers include gastroparesis (delayed gastric emptying, often tied to diabetes), vestibular disorders like benign paroxysmal positional vertigo (BPPV), early-stage hepatitis, and adrenal insufficiency. A 2019 systematic review published in The Lancet Gastroenterology & Hepatology found that functional nausea meeting Rome IV criteria accounts for up to 10% of patients referred to gastroenterology clinics when no structural or biochemical cause is identified [5]. Anxiety and panic disorder also trigger nausea through vagal nerve activation, a connection patients and clinicians sometimes miss.

Red-Flag Symptoms: When Nausea Signals an Emergency

Go to the emergency department now if nausea appears with any of the following. These warrant immediate evaluation, not a "wait and see" approach.

Hematemesis (bloody or coffee-ground vomit). This suggests upper GI bleeding from a peptic ulcer, Mallory-Weiss tear, or esophageal varices. A BMJ clinical review on upper GI bleeding notes that mortality for acute variceal hemorrhage still runs between 15 and 20% per episode without rapid intervention [6].

Severe headache with neck stiffness and photophobia. Nausea combined with these features raises concern for meningitis or subarachnoid hemorrhage. Time to antibiotics or neurosurgical consultation is measured in minutes.

Chest pain, jaw pain, or diaphoresis. The American Heart Association notes that nausea and vomiting are presenting symptoms in roughly 35% of myocardial infarctions, particularly in women, older adults, and patients with diabetes [7]. Isolated nausea may be the only complaint.

Abdominal rigidity or rebound tenderness. These suggest peritonitis from a perforated viscus or advanced appendicitis. Surgical consultation should not be delayed for imaging.

Signs of severe dehydration. Absent urine output for more than 12 hours, tachycardia, sunken eyes, and altered mental status mean oral rehydration has failed. IV fluids and electrolyte correction are necessary.

Projectile vomiting with no prior nausea. In adults, new-onset projectile vomiting raises concern for increased intracranial pressure (tumor, abscess, or hydrocephalus) and requires urgent neuroimaging.

Dr. Mark Feldman, former president of the American College of Gastroenterology, has written: "The clinical challenge with nausea is not the common causes. It is recognizing the uncommon but dangerous ones before they declare themselves fully" [8].

How Doctors Diagnose Persistent Nausea

A focused history answers most of the diagnostic question. Timing (morning, postprandial, constant), duration, associated symptoms, medication list, and menstrual history direct the workup more efficiently than blanket testing.

Initial laboratory evaluation typically includes a complete blood count (CBC), basic metabolic panel (BMP), serum lipase, liver function tests, thyroid-stimulating hormone (TSH), and a pregnancy test for individuals of childbearing potential. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) recommends adding a gastric emptying scintigraphy (GES) study when gastroparesis is suspected, using a standardized low-fat egg meal measured at 1, 2, 3, and 4 hours [9]. Retention of more than 10% at 4 hours confirms the diagnosis.

Upper endoscopy (EGD) is indicated when nausea accompanies alarm features: unintentional weight loss exceeding 5% of body weight, dysphagia, persistent vomiting, iron deficiency anemia, or age over 60 with new-onset symptoms. The American Gastroenterological Association (AGA) guidelines recommend against routine EGD for nausea alone in patients under 60 without red flags [10].

Cross-sectional imaging (CT abdomen/pelvis with contrast) enters the picture when obstruction, pancreatitis, or an intra-abdominal mass is suspected. For patients with chronic nausea and a clean structural workup, wireless motility capsule testing or antroduodenal manometry can evaluate for motility disorders that standard imaging misses.

The Rome IV criteria for chronic nausea and vomiting disorders require symptoms present for at least 3 days per week over the last 3 months, with symptom onset at least 6 months before diagnosis, and no identified structural or metabolic explanation after appropriate evaluation [5].

Medical Treatment Options for Nausea

Antiemetic choice depends on the mechanism driving nausea. Blindly prescribing one drug for all presentations is poor practice because the neurotransmitter pathways differ.

Ondansetron (Zofran). A 5-HT3 receptor antagonist and the most widely prescribed antiemetic in emergency departments. A Cochrane systematic review of 41 trials found ondansetron significantly reduces vomiting (RR 0.45 to 95% CI 0.37 to 0.55) compared with placebo in acute gastroenteritis [11]. Standard dosing is 4 to 8 mg orally or IV every 8 hours. The oral disintegrating tablet (ODT) formulation dissolves on the tongue, which helps when a patient cannot keep pills down. QTc prolongation is a known risk at higher doses.

Promethazine (Phenergan). A first-generation antihistamine with dopamine antagonist properties. Effective for vestibular nausea and motion sickness but causes significant sedation. The FDA issued a boxed warning for severe tissue injury with intravenous or intra-arterial injection, recommending deep intramuscular injection only [12].

Metoclopramide (Reglan). A prokinetic dopamine antagonist. Useful in gastroparesis because it accelerates gastric emptying in addition to reducing nausea. The FDA limits treatment duration to 12 weeks due to the risk of tardive dyskinesia, which occurs in approximately 1 to 10% of patients on long-term therapy [13].

Prochlorperazine (Compazine). A phenothiazine dopamine antagonist particularly effective for migraine-associated nausea. A randomized trial published in Annals of Emergency Medicine (N=208) found prochlorperazine 10 mg IV reduced nausea scores by 68% at 30 minutes versus 33% for ondansetron [14].

Dronabinol and medical cannabis. The FDA has approved dronabinol for chemotherapy-induced nausea refractory to conventional antiemetics [15]. Evidence for other causes of nausea remains limited and conflicting.

According to the 2023 AGA clinical practice update on nausea management: "Empiric antiemetic therapy should be directed at the most likely underlying mechanism rather than applied as a uniform protocol" [10].

When to Schedule a Non-Urgent Appointment

Not all nausea that requires medical attention requires an ambulance. Several patterns warrant a scheduled clinic visit rather than emergency care.

Nausea lasting longer than two weeks. Anything beyond the typical viral or self-limited course deserves investigation. A basic laboratory panel and medication review are the minimum starting point.

Nausea with unintentional weight loss. Losing more than 5% of body weight over 6 to 12 months alongside nausea raises the priority for upper endoscopy and cross-sectional imaging. A population-based study in The BMJ (N=25,000+) found that unexplained weight loss in adults over 60 carries a 1-year cancer risk of roughly 6 to 10% depending on sex and magnitude of loss [16].

Nausea associated with a new medication. GLP-1 receptor agonists, antibiotics, and chemotherapeutics top this list. Dose adjustment or switching within the drug class often resolves the issue without discontinuing therapy. Your prescriber should know before your next injection or refill.

Recurrent morning nausea (outside of pregnancy). This pattern raises suspicion for increased intracranial pressure, adrenal insufficiency, or GERD with nocturnal reflux causing morning symptoms.

Cyclic vomiting syndrome (CVS). Episodes of intense nausea and vomiting lasting hours to days, separated by symptom-free intervals, characterize CVS. The Rome IV diagnostic criteria require at least 3 discrete episodes in the prior year with 2 in the last 6 months, occurring at least 1 week apart, with no vomiting between episodes [17]. Amitriptyline at 25 to 75 mg nightly is the first-line prophylactic in adults.

GLP-1 Medications and Nausea: What Patients Should Know

Nausea is the most commonly reported adverse effect of GLP-1 receptor agonists, and patients starting semaglutide or tirzepatide should anticipate it rather than fear it.

In the STEP-1 trial (N=1,961), 44.2% of patients on semaglutide 2.4 mg reported nausea compared with 17.8% on placebo [18]. The nausea was predominantly mild to moderate and peaked during dose escalation (weeks 4 through 8), then subsided for most participants. Only 4.5% of subjects in the semaglutide arm discontinued treatment due to GI side effects.

The SURMOUNT-1 trial (N=2,539) of tirzepatide at its highest dose (15 mg) reported nausea in 31.0% of participants, with most episodes rated mild and occurring early in the escalation phase [19]. Discontinuation for nausea alone was under 3%.

Practical management strategies include:

• Slower dose escalation. Many prescribers extend the time at each dose tier from 4 weeks to 6 or 8 weeks if nausea is limiting.
• Smaller meals. Eating past the point of comfortable fullness amplifies GLP-1-related nausea because gastric emptying is already slowed.
• Avoid high-fat foods during escalation. Fat delays emptying further and worsens the early-satiety/nausea feedback loop.
• Ondansetron as rescue therapy. An ODT 4 mg tablet as needed is frequently prescribed alongside GLP-1 therapy during the escalation window.

The nausea of GLP-1 therapy is a pharmacologic effect of delayed gastric emptying and central appetite suppression, not a sign of toxicity. Patients who push through the initial weeks with appropriate support typically see resolution by the time they reach maintenance dosing.

Home Management Strategies With Clinical Support

For mild, self-limited nausea (viral illness, dietary indiscretion, motion sickness), several non-prescription approaches have evidence behind them.

Ginger. A meta-analysis of 12 randomized controlled trials published on PubMed found that ginger at doses of 1,000 to 1 to 500 mg/day significantly reduced nausea severity (standardized mean difference of -0.31 to 95% CI -0.49 to -0.12) with no serious adverse effects [20]. Capsule forms are more reliably dosed than ginger tea or ginger ale.

Oral rehydration solutions (ORS). The WHO ORS formulation (75 mEq/L sodium, 75 mmol/L glucose, 245 mOsm/L) is designed specifically for rehydration during vomiting and diarrhea [21]. Sports drinks have too much sugar and too little sodium for clinical rehydration purposes. Small sips of 5 to 15 mL every 5 minutes are more effective than large gulps.

Acupressure at the P6 (Neiguan) point. Located on the inner wrist, three finger-widths below the palm crease. A Cochrane review found consistent evidence that P6 acupressure reduces postoperative nausea and vomiting compared with sham stimulation [22]. Commercial wristbands (Sea-Bands) apply pressure at this point and are available without prescription.

Dietary approach. The traditional BRAT diet (bananas, rice, applesauce, toast) has no formal trial data but remains a reasonable short-term strategy because these foods are low in fat, low in fiber, and unlikely to trigger further nausea. Avoid dairy, caffeine, alcohol, and spicy foods until symptoms resolve.

Positioning. Lying on the left side reduces gastric pressure against the lower esophageal sphincter. Elevating the head of the bed by 30 degrees helps patients with reflux-mediated nausea.

Stop home management and seek care if you cannot keep any fluids down for more than 12 hours, if you develop a fever above 39°C (102.2°F), or if abdominal pain becomes focal and worsening.

Nausea in Specific Populations

Certain groups face unique risks that change the clinical calculus.

Older adults (age 65+). Nausea with vomiting accelerates dehydration and electrolyte imbalance faster in older patients because of reduced total body water and decreased renal concentrating ability. Hyponatremia from vomiting-induced volume depletion can cause confusion and falls. The threshold for IV rehydration should be lower.

Patients on anticoagulants. Vomiting in someone taking warfarin, apixaban, or rivarelbano raises the risk of missed doses and erratic INR. Coffee-ground emesis in an anticoagulated patient should be treated as a GI bleed until proven otherwise.

Post-surgical patients. Postoperative nausea and vomiting (PONV) affects 30% of general surgical patients and up to 80% of high-risk patients (female, non-smoker, history of PONV or motion sickness, receiving opioids). The Apfel simplified risk score uses four factors to predict PONV risk: female sex, non-smoking status, history of PONV/motion sickness, and postoperative opioid use [23]. Each factor present adds approximately 20 percentage points of risk.

Patients on chemotherapy. Chemotherapy-induced nausea and vomiting (CINV) is classified by emetogenic potential of the regimen. High-emetogenic regimens (cisplatin, AC combinations) require triple antiemetic prophylaxis: a 5-HT3 antagonist, dexamethasone, and an NK1 receptor antagonist (aprepitant 125 mg day 1, then 80 mg days 2 and 3). The ASCO antiemesis guidelines were updated in 2020 and recommend adding olanzapine 10 mg on days 1 through 4 for high-risk patients [24].

For adults with persistent nausea lasting more than 4 weeks despite empiric antiemetic therapy, the AGA recommends referral to gastroenterology for Rome IV-based evaluation and consideration of specialized motility testing [10].